- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exenatide, Glargine Insulin
- Drug
- Lead sponsor
- Joslin Diabetes Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–6
of 6
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes
- Interventions
- Exenatide, Glargine, Rapid-acting insulin analogs
- Drug
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Insulin lispro, recombinant human hyaluronidase PH20, Insulin aspart, Insulin glulisine, Insulin glargine
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 19
- States / cities
- Escondido, California • La Jolla, California • San Mateo, California + 16 more
- Conditions
- Frontotemporal Dementia, Behavioral Variant
- Interventions
- Novolin-R insulin
- Drug
- Lead sponsor
- HealthPartners Institute
- Other
- Eligibility
- 41 Years to 89 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Saint Paul, Minnesota
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Insulin lispro, Insulin aspart, Recombinant human hyaluronidase PH20, Insulin glulisine, Insulin glargine
- Drug
- Lead sponsor
- Halozyme Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 22
- States / cities
- Concord, California • Encino, California • Escondido, California + 18 more
- Conditions
- Glaucoma
- Interventions
- Insulin, 4 units, Insulin, 20 units, insulin, 4 units twice daily, insulin, 20 units twice daily, insulin, 4 units three times daily, insulin, 20 units three times daily
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Palo Alto, California